Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Pharmacogenomic considerations in opioid analgesia.

Vuilleumier PH, Stamer UM, Landau R.

Pharmgenomics Pers Med. 2012;5:73-87. doi: 10.2147/PGPM.S23422. Epub 2012 Aug 23. Erratum in: Pharmgenomics Pers Med. 2013;6:1.

2.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Zhou SF.

Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.

PMID:
19902987
3.

CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.

Balyan R, Mecoli M, Venkatasubramanian R, Chidambaran V, Kamos N, Clay S, Moore DL, Mavi J, Glover CD, Szmuk P, Vinks A, Sadhasivam S.

Pharmacogenomics. 2017 Mar;18(4):337-348. doi: 10.2217/pgs-2016-0183. Epub 2017 Feb 17.

PMID:
28244808
4.

CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.

VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, Hayden MR, Koren G.

Ther Drug Monit. 2011 Aug;33(4):425-32. doi: 10.1097/FTD.0b013e3182272b10.

PMID:
21743374
5.

CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.

Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Musshoff F.

PLoS One. 2013;8(3):e60239. doi: 10.1371/journal.pone.0060239. Epub 2013 Mar 28.

6.

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.

Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA.

Br J Pharmacol. 2010 Jun;160(4):919-30. doi: 10.1111/j.1476-5381.2010.00709.x.

7.

Pharmacogenomics of opioids and perioperative pain management.

Sadhasivam S, Chidambaran V.

Pharmacogenomics. 2012 Nov;13(15):1719-40. doi: 10.2217/pgs.12.152. Review.

PMID:
23171337
8.

Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.

Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH.

Acta Anaesthesiol Scand. 2010 Feb;54(2):232-40. doi: 10.1111/j.1399-6576.2009.02104.x. Epub 2009 Aug 31.

PMID:
19719813
9.

Morphine or oxycodone in cancer pain?

Heiskanen TE, Ruismäki PM, Seppälä TA, Kalso EA.

Acta Oncol. 2000;39(8):941-7.

PMID:
11207001
10.

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.

Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA.

Br J Pharmacol. 2010 Jun;160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x.

11.

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.

Bell GC, Donovan KA, McLeod HL.

Cancer Control. 2015 Oct;22(4):426-32. Review.

12.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
13.

Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial.

Riley J, Branford R, Droney J, Gretton S, Sato H, Kennett A, Oyebode C, Thick M, Wells A, Williams J, Welsh K, Ross J.

J Pain Symptom Manage. 2015 Feb;49(2):161-72. doi: 10.1016/j.jpainsymman.2014.05.021. Epub 2014 Jun 26.

PMID:
24975432
14.

Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?

Madadi P, Sistonen J, Silverman G, Gladdy R, Ross CJ, Carleton BC, Carvalho JC, Hayden MR, Koren G.

Pain Res Manag. 2013 May-Jun;18(3):133-6.

15.

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.

Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, Dale O.

Eur J Clin Pharmacol. 2012 Jan;68(1):55-64. doi: 10.1007/s00228-011-1093-5. Epub 2011 Jul 7.

16.

[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].

Naito T, Kawakami J.

Yakugaku Zasshi. 2015;135(5):709-15. doi: 10.1248/yakushi.14-00234-4. Review. Japanese.

17.

Efficacy and safety of dual-opioid therapy in acute pain.

Webster L.

Pain Med. 2012 Mar;13 Suppl 1:S12-20. doi: 10.1111/j.1526-4637.2012.01330.x. Review.

PMID:
22420602
18.

Glial Modulation in Pain States: Translation into Humans.

Horvath RJ, Romero-Sandoval EA, De Leo JA.

In: Kruger L, Light AR, editors. Translational Pain Research: From Mouse to Man. Boca Raton, FL: CRC Press/Taylor & Francis; 2010. Chapter 9.

19.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Zhou SF.

Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Review.

PMID:
19817501

Supplemental Content

Support Center